OBJECTIVE: To determine the incidence of antiendothelial cell antibodies in diabetic patients with and without retinopathy. RESEARCH DESIGN AND METHODS: The study consisted of 70 insulin-dependent diabetic (IDDM) subjects, 36 non-insulin-dependent diabetic (NIDDM) subjects, and 40 nondiabetic control subjects. Blood samples were obtained from diabetic patients and control subjects and patients with background and proliferative retinopathy were identified. RESULTS: Vascular endothelial cell (VEC) antibodies were examined in the sera of 36 NIDDM subjects, 70 IDDM subjects, and 40 nondiabetic control subjects by indirect immunofluorescence. VEC antibodies were present in 5 of 40 (12%) control subjects, 7 of 23 (30%) newly diagnosed IDDM patients, 6 of 17 (35%) IDDM patients without retinopathy, 12 of 18 (67%) IDDM patients with background retinopathy (P less than 0.05), and 9 of 12 (75%) IDDM patients with proliferative retinopathy (P less than 0.01). Three of 13 (23%) NIDDM patients with retinopathy and 6 of 23 (26%) without retinopathy were VEC antibody positive. No associations were observed between the presence of VEC antibodies and either the quality of glycemic control or the duration of diabetes. A significant association between VEC antibodies and large-vessel disease was found in IDDM patients with retinopathy (P less than 0.05). CONCLUSIONS: Antibodies directed against vascular endothelial cells may play a role in the development of microvascular, and possibly macrovascular, disease in diabetes.
OBJECTIVE: To determine the incidence of antiendothelial cell antibodies in diabeticpatients with and without retinopathy. RESEARCH DESIGN AND METHODS: The study consisted of 70 insulin-dependent diabetic (IDDM) subjects, 36 non-insulin-dependent diabetic (NIDDM) subjects, and 40 nondiabetic control subjects. Blood samples were obtained from diabeticpatients and control subjects and patients with background and proliferative retinopathy were identified. RESULTS: Vascular endothelial cell (VEC) antibodies were examined in the sera of 36 NIDDM subjects, 70 IDDM subjects, and 40 nondiabetic control subjects by indirect immunofluorescence. VEC antibodies were present in 5 of 40 (12%) control subjects, 7 of 23 (30%) newly diagnosed IDDMpatients, 6 of 17 (35%) IDDMpatients without retinopathy, 12 of 18 (67%) IDDMpatients with background retinopathy (P less than 0.05), and 9 of 12 (75%) IDDMpatients with proliferative retinopathy (P less than 0.01). Three of 13 (23%) NIDDMpatients with retinopathy and 6 of 23 (26%) without retinopathy were VEC antibody positive. No associations were observed between the presence of VEC antibodies and either the quality of glycemic control or the duration of diabetes. A significant association between VEC antibodies and large-vessel disease was found in IDDMpatients with retinopathy (P less than 0.05). CONCLUSIONS: Antibodies directed against vascular endothelial cells may play a role in the development of microvascular, and possibly macrovascular, disease in diabetes.
Authors: P Gargiulo; J Goldberg; B Romani; R Schiaffini; P Ciampalini; W P Faulk; J A McIntyre Journal: Clin Exp Immunol Date: 1999-10 Impact factor: 4.330
Authors: Dongxu Fu; Jeremy Y Yu; Mingyuan Wu; Mei Du; Ying Chen; Souzan A Abdelsamie; Yanchun Li; Junping Chen; Michael E Boulton; Jian-Xing Ma; Maria F Lopes-Virella; Gabriel Virella; Timothy J Lyons Journal: J Lipid Res Date: 2014-03-10 Impact factor: 5.922
Authors: C Giusti; R Schiaffini; D Bosco; P Ciampalini; A Pantaleo; E M Vingolo; P Gargiulo Journal: Br J Ophthalmol Date: 2000-05 Impact factor: 4.638
Authors: Michael A Zimmerman; Kathryn Haskins; Brenda Bradley; Jessica Gilman; Fabia Gamboni-Robertson; Sonia C Flores Journal: J Surg Res Date: 2011-02-26 Impact factor: 2.192
Authors: G Triolo; G Triolo; A Accardo-Palumbo; M C Carbone; A Ferrante; D Casiglia; E Giardina Journal: Clin Exp Immunol Date: 1998-03 Impact factor: 4.330